Close menu




November 5th, 2021 | 11:22 CET

BioNTech, Sativa Wellness, Merck KGaA - Impressive trend

  • Biotechnology
Photo credits: pixabay.com

There is no question that vaccine manufacturers are one of the main winners of the Corona pandemic. The recently presented quarterly figures of Pfizer, BioNTech's partner, show this impressively and suggest that the Mainz-based Company will also announce a sales explosion on November 9. Booster vaccinations are likely to continue this trend. Currently, encouraged by legalization, the cannabis industry is also experiencing a new upswing. Be a part of it from the beginning.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , SATIVA WELLNESS GROUP INC | CA80403E1043 , MERCK KGAA O.N. | DE0006599905

Table of contents:


    BioNTech - Plenty of potential

    The latest figures from the Robert Koch Institute show the potential of the vaccine manufacturers' business. According to these figures, only 55.6 million people in Germany have been fully vaccinated. This number corresponds to 66.9% of the population in the Federal Republic. Of these, only 2.4 million people have received a booster vaccination. This topic is likely to represent another significant revenue driver for BioNTech. It is true that the Standing Commission on Vaccination (STIKO) has so far recommended booster vaccinations for people aged 70 and over. A decision on whether booster vaccinations should be offered to everyone is therefore likely to follow soon.

    Another target group is children between the ages of five and eleven. Good news is now coming from the United States, where BioNTech and Pfizer's COVID-19 vaccine Comirnaty has now received the expected approval of a health authority expert panel, following emergency approval. As of now, the vaccination campaign for nearly 30 million children in the US can begin. In addition to the US, BioNTech and Pfizer have applied for approval of their Corona vaccine for children in Europe in the middle of last month. The EU Medicines Agency (EMA) is expected to come up with a decision soon.

    The stock is currently trading at around USD 295.00, and a breakout above the USD 304.15 level would generate potential to around USD 340.00. Given the above-mentioned next steps, little should stand in the way of a renewed bull run.

    Sativa Wellness - Wide range

    With the legalization of cannabis in several states, the industry faces a prosperous future in the coming years. Add to that the fact that products centered around the cannabis plant will occupy the billion-dollar health and recreational sectors in the next wave. Sativa Wellness, a Canadian company with operations in the UK, plans to become one of the big players in producing and distributing high-quality CBD products and CBD services in Europe.

    In doing so, Sativa Wellness' business model stands on three legs that run entirely separately from each other. Under Goodbody Botanicals, CBD products developed on a gold standard basis are produced for the end consumer. In a strictly regulated European health segment, PhytoVista has also become one of the top three CBD and hemp testing laboratories on the continent. The third brand, Goodbody Wellness, offers testing services for clinics and direct-to-consumer and direct-to-business services via a telemedicine consulting service.

    The opening of the 70th Goodbody clinic was announced here. The "Virtual GP Service" offers all of its customers the ability to follow up on their wellness test results with a virtual medical consultation. Now the plan is to develop a portfolio of private healthcare services. With the rapidly growing network of clinics, access to physician consultations is the next logical step in offering a complete wellness solution.

    After a management change and complete realignment, the new structure is already taking full effect. Sales exploded by 828% to EUR 4.17 million in the second quarter compared to the same quarter last year. Gross profit increased by 804% to EUR 2.29 million compared to the same quarter in 2020. The gross margin here was 55%. Sativa is on a good path and is setting an impressive pace to significantly increase the currently still manageable stock market value of EUR 16.48 million.

    Merck - The vaccine profiteer

    Even in the BioNTech haze, companies can continue to profit due to the Corona pandemic. The following success story comes from Darmstadt, where Merck KGaA is based. The DAX-listed Company works closely with BioNTech and supplies urgently needed lipids to Mainz. The lipids are used in the production of the COVID-19 vaccine Comirnaty and are essential for the drug release of mRNA therapeutics in the body. They enable a vaccine to exert its effect.

    Based on the solid third quarter, the pharmaceutical and specialty chemicals group has raised its full-year forecasts again. The last increase in the outlook was in August of this year. Full-year sales are expected to grow from EUR 19.30 billion to EUR 19.85 billion, up from EUR 17.5 billion in 2020. Previous estimates were EUR 18.80 billion to EUR 19.70 billion. Earnings before interest, taxes, depreciation and amortization adjusted for special items are expected to grow from EUR 5.2 billion in the previous year to EUR 6.0 to 6.3 billion. The previous forecast was EUR 5.6 to 6.0 billion.

    The full set of figures for the Darmstadt-based Company will be published on November 11. Following the figures, the British investment bank Barclays took the floor and reiterated its "overweight" rating with a target price of EUR 215.


    The pandemic will accompany society for a while yet. Booster vaccinations provide recurring revenue for vaccine makers such as BioNTech and those around them such as pharmaceutical and specialty chemicals group Merck. The CBD market is growing rapidly. The Sativa Wellness Group is well-positioned in this regard and has long-term potential.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on May 12th, 2022 | 13:07 CEST

    Cardiol Therapeutics, Tesla, Bayer AG - Instead of trading chronically overvalued shares, treat the chronically ill instead

    • Biotechnology

    No sooner does the US government under Biden seek to influence the Supreme Court in the Monsanto case than the Bayer share slides 7%. But is this share price slide justified? Bayer AG has made provisions for the possible ruling in June and set aside reserves for chronic diseases. Chronic diseases are also a focus of Cardiol Therapeutics. According to the World Health Organization (WHO), the prevalence of chronic diseases increased by 57% worldwide by 2020. Cardiol focuses on heart health in this regard. The share stands at about EUR 1.12 and is seen by analysts at an average of about EUR 7. Meanwhile, Tesla investors are currently experiencing what overvalued shares can do to their portfolios. Their CEO is speculating that he will no longer accept new customers. Why? You can read about it here...

    Read

    Commented by Fabian Lorenz on May 12th, 2022 | 11:12 CEST

    BioNTech, BYD and Desert Gold: Shares for the rebound

    • Gold
    • Electromobility
    • Biotechnology

    Is the rebound coming? After the heavy price losses of recent days and weeks, the market seems ripe for a countermovement. However, this would require a little more volume in the market. But then, especially companies that have not disappointed operationally should profit. BioNTech, for example, belongs to this group. The Company has published convincing figures, and analysts see up to 50% price potential. BYD's share price should also pick up speed again. Finally, the rapid shift to electric pureplay seems to be succeeding and HSBC has raised the price target. Gold was not a safe haven in the current correction. But it is worth looking at bombed-out stocks here as well. Desert Gold Ventures is one of them. The explorer has started a new drill program and secured financing.

    Read

    Commented by Juliane Zielonka on May 10th, 2022 | 12:38 CEST

    Biotech stocks: Defence Therapeutics, BioNTech, BASF - Advantage through platform technology

    • Biotechnology

    Large corporations such as BASF were previously considered safe portfolio investments. But the war in Ukraine is throwing a spanner in the works. Force majeure, such as war, can cause deals to fall through without the responsibility of the companies involved. How should investors react now? Which portfolio strategy can keep up with the high volatility of the markets? Newcomers like BioNTech face oversupply and have to accept shortages. A focus on emerging markets seems to be the solution for their growth strategy. But there are subtle differences in the vaccines business, as Defence Therapeutics proves.

    Read